Therachon

Short Bowel Syndrome

Our Focus Short Bowel Syndrome

We are working on the development of a best-in-class therapy for patients with unmet medical needs related to SBS. Our investigational Apraglutide product candidate has demonstrated potential for superior efficacy, regimen and tolerability, as well as a more predictable patient response.

Short Bowel Syndrome (SBS) results from extensive intestinal resection due to chronic Inflammatory Bowel Disease (IBD), acute events (e.g. mesenteric infarction) or congenital abnormalities.

It is estimated that between 20,000 and 40,000 people are living with short bowel syndrome in the United States and Europe.

Patients with SBS require life-long parenteral support, which involves providing the body’s nutritional needs via intravenous drip rather than eating or drinking.

The current standard for care for SBS includes:

Nutritional Support,
Medication

Parentarel Support
(PS)

GLP-2 Analogs

Our Apraglutide product candidate, a next-generation, synthetic GLP-2 analog with a potentially best-in-class profile, aims to improve on:

Efficacy
Convenience
Adherence

A Phase 1 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) clinical trial was successfully completed in healthy volunteers. Two Phase 2 studies in two distinct SBS populations – patients with Intestinal Failure and patients with Intestinal Insufficiency – are underway.

View Our Pipeline